Education
About Us
Working with TipRanks
Follow Us
Nutriband Inc (NTRB)
NASDAQ:NTRB
NTRB Stock Chart & Stats
$4.53
-$0.10(-2.25%)
At close: 4:00 PM EST
$4.53
-$0.10(-2.25%)
Day’s Range― - ―
52-Week Range$3.72 - $11.78
Previous CloseN/A
Volume13.23K
Average Volume (3M)31.62K
Market Cap
$53.33M
Enterprise Value$59.94M
Total Cash (Recent Filing)$5.31M
Total Debt (Recent Filing)$216.42K
Price to Earnings (P/E)―
Beta1.45
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding12,174,883
10 Day Avg. Volume33,995
30 Day Avg. Volume31,617
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)13.68
Price to Sales (P/S)41.09
P/FCF Ratio-18.63
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue26.31
Enterprise Value/Gross Profit80.61
Enterprise Value/Ebitda-4.76
Forecast
1Y Price Target
$15.00Price Target Upside231.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market GrowthThe additional safety from the abuse-deterrent technology could potentially grow the market and drive upward revisions to estimates.
PartnershipsNutriband has a partnership with Kindeva Drug Delivery, formerly part of 3M, to add the AVERSA technology to Kindeva’s transdermal fentanyl patch.
Product DevelopmentThe AVERSA Fentanyl patch could prevent abuse and accidental misuse of fentanyl transdermal patches.
Bears Say
Development CostsNutriband and its partner, Kindeva, have amended their development and commercialization agreement covering AVERSA Fentanyl, the abuse-deterrent transdermal fentanyl patch in development.
Nutriband News
NTRB FAQ
What was Nutriband Inc’s price range in the past 12 months?
Nutriband Inc lowest stock price was $3.72 and its highest was $11.78 in the past 12 months.
What is Nutriband Inc’s market cap?
Nutriband Inc’s market cap is $53.33M.
When is Nutriband Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nutriband Inc’s earnings last quarter?
Nutriband Inc released its earnings results on May 28, 2024. The company reported -$0.207 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.207.
Is Nutriband Inc overvalued?
According to Wall Street analysts Nutriband Inc’s price is currently Undervalued.
Does Nutriband Inc pay dividends?
Nutriband Inc does not currently pay dividends.
What is Nutriband Inc’s EPS estimate?
Nutriband Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nutriband Inc have?
Nutriband Inc has 12,174,883 shares outstanding.
What happened to Nutriband Inc’s price movement after its last earnings report?
Nutriband Inc reported an EPS of -$0.207 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Nutriband Inc?
Currently, no hedge funds are holding shares in NTRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nutriband Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (231.13% Upside)
$15.00 (231.13% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.9%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.35%
12-Months-Change
Fundamentals
Return on Equity
-98.00%
Trailing 12-Months
Asset Growth
-25.36%
Trailing 12-Months
Company Description
Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
NTRB Stock 12 Month Forecast
Average Price Target
$15.00
▲(231.13% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.87% Mutual Funds
0.09% Other Institutional Investors
96.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---